Presentation is loading. Please wait.

Presentation is loading. Please wait.

Figure 6 Effects of adiponectin on podocyte function

Published byKelley Greene Modified over 6 years ago

Similar presentations

Presentation on theme: "Figure 6 Effects of adiponectin on podocyte function"— Presentation transcript:

1 Figure 6 Effects of adiponectin on podocyte function
Figure 6 | Effects of adiponectin on podocyte function. Increased adipose mass leads to decreased levels of adiponectin and reduced activation of the adiponectin receptor on podocytes, reduced AMPK activation and increased inflammation. In mice, lack of adiponectin leads to foot process effacement and albuminuria. The early onset of albuminuria in patients with obesity and hypertension might also be associated with reduced adiponectin levels. Câmara, N. O. S. et al. (2017) Kidney disease and obesity: epidemiology, mechanisms and treatment Nat. Rev. Nephrol. doi: /nrneph

Download ppt "Figure 6 Effects of adiponectin on podocyte function"

Similar presentations

Figure 1 Schematic representation of idiopathic nephrotic syndrome,

Figure 1 Schematic representation of idiopathic nephrotic syndrome,
Nat. Rev. Nephrol. doi: /nrneph

Nat. Rev. Nephrol. doi: /nrneph
Figure 5 A layered approach to the follow-up of patients with acute kidney disease (AKD) Figure 5 | A layered approach to the follow-up of patients with.

Figure 5 A layered approach to the follow-up of patients with acute kidney disease (AKD) Figure 5 | A layered approach to the follow-up of patients with.
Figure 4 Interplay between acute kidney injury (AKI),

Figure 4 Interplay between acute kidney injury (AKI),
Figure 4 The theoretical contribution of genetic and

Figure 4 The theoretical contribution of genetic and
Figure 5 Inter-relationships between sleep apnoea, CKD and brain injury Figure 5 | Inter-relationships between sleep apnoea, CKD and brain injury. In chronic.

Figure 5 Inter-relationships between sleep apnoea, CKD and brain injury Figure 5 | Inter-relationships between sleep apnoea, CKD and brain injury. In chronic.
Figure 6 Differences in glycaemic control with the study drug

Figure 6 Differences in glycaemic control with the study drug
Figure 6 Approach to drug management in patients with acute kidney disease (AKD) Figure 6 | Approach to drug management in patients with acute kidney disease.

Figure 6 Approach to drug management in patients with acute kidney disease (AKD) Figure 6 | Approach to drug management in patients with acute kidney disease.
Figure 4 Expression of coagulation protease receptors in renal cells

Figure 4 Expression of coagulation protease receptors in renal cells
Figure 3 Angiotensin signalling in adiporenal crosstalk

Figure 3 Angiotensin signalling in adiporenal crosstalk
Figure 4 Interactions between adipose, the microbiome and kidney

Figure 4 Interactions between adipose, the microbiome and kidney
Nat. Rev. Nephrol. doi: /nrneph

Nat. Rev. Nephrol. doi: /nrneph
Figure 1 Mechanisms of kidney injury in the setting of obesity

Figure 1 Mechanisms of kidney injury in the setting of obesity
Figure 2 Proinflammatory mechanisms in CKD

Figure 2 Proinflammatory mechanisms in CKD
Figure 3 The fat–intestine–kidney axis

Figure 3 The fat–intestine–kidney axis
Nat. Rev. Nephrol. doi: /nrneph

Nat. Rev. Nephrol. doi: /nrneph
Figure 4 BMI and mortality in patients with heart failure

Figure 4 BMI and mortality in patients with heart failure
Figure 1 Pathologic features of obesity-related glomerulopathy (ORG)

Figure 1 Pathologic features of obesity-related glomerulopathy (ORG)
Nat. Rev. Nephrol. doi: /nrneph

Nat. Rev. Nephrol. doi: /nrneph
Nat. Rev. Cardiol. doi: /nrcardio

Nat. Rev. Cardiol. doi: /nrcardio

Similar presentations

Ads by Google